Cargando…

163. Enhancing the Immunogenicity of a Novel, Low-cost Ebola Vaccine

BACKGROUND: Ebolaviruses cause viral hemorrhagic fever with high mortality rates. Nearly all Ebola vaccines in development use Ebola glycoprotein (GP) as the immunizing antigen. GP is present on the viral membrane and functions in cell entry by binding the cellular receptor and mediating membrane fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stampfer, Samuel D, Jin, Rui, Yang, Chinglai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776394/ http://dx.doi.org/10.1093/ofid/ofaa439.473

Ejemplares similares

163. Automation of an Inpatient Provider Specific Antimicrobial Use Report
por: Weslander, Erin, et al.
Publicado: (2020)

1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults
por: Chichili, Gurunadh, et al.
Publicado: (2020)

T163. Submission Withdrawn
Publicado: (2018)

Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus
por: Mohan, Gopi S., et al.
Publicado: (2012)

163. MIC Shifts in Response to Increased Antibiotic Utilization During COVID-19 Pandemic
por: Byrd, Jonathan, et al.
Publicado: (2021)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

1285. Identification of KPC Omega Loop Variant R163S Conferring Ceftazidime-Avibactam Resistance
por: Maris, Alexander S, et al.
Publicado: (2021)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021)

579. Design and Immunogenicity of a Pan-SARS-CoV-2 Synthetic DNA Vaccine
por: Schultheis, Katherine, et al.
Publicado: (2021)

An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination
por: Xia, Dengning, et al.
Publicado: (2021)

774. Sexual Behaviors and Attitudes of Intimate Partners of Ebola Survivors
por: Cunningham, Hannah M, et al.
Publicado: (2020)

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
por: Joyce, M G, et al.
Publicado: (2021)

Improving blood transfusion safety in a low-resource setting: an audit of 1,163 transfusion requests
por: Kudsk-Iversen, S, et al.
Publicado: (2015)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
por: Tebas, Pablo, et al.
Publicado: (2021)

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2020)

Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity
por: Agnolon, Valentina, et al.
Publicado: (2020)

08. Concomitant Administration of the Adjuvanted Recombinant Zoster Vaccine (RZV) with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Is Safe and Does Not Interfere with Immunogenicity of Either Vaccine in Adults Aged ≥ 50 Years
por: Min, Ji-Young, et al.
Publicado: (2021)

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
por: Tasker, Sybil, et al.
Publicado: (2018)

636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)
por: Russell, Kevin, et al.
Publicado: (2021)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age
por: Chang, Leejah, et al.
Publicado: (2020)

S163. FEASIBILITY STUDY: MEASURES OF SLEEP AND PHYSICAL ACTIVITY IN PEOPLE WITH SCHIZOPHRENIA
por: Berry, Alexandra, et al.
Publicado: (2018)

10061 Assessing immunogenicity of an Ebola vaccine in humans using a systems biology approach
por: Martin, Olivia, et al.
Publicado: (2021)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Cationic Polymers for the Delivery of the Ebola DNA Vaccine Encoding Artificial T-Cell Immunogen
por: Karpenko, Larisa I., et al.
Publicado: (2020)

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans
por: McElroy, Anita K., et al.
Publicado: (2019)

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier
por: Peterson, James, et al.
Publicado: (2021)

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan
por: Matsuoka, Osamu, et al.
Publicado: (2021)

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)
por: Banniettis, Natalie, et al.
Publicado: (2021)

870. Coverage, Cost Sharing, and Out-of-Pocket Costs for Single-Tablet HIV Antiretroviral Regimens in Qualified Health Plans in the United States, 2018-2020
por: Khazanchi, Rohan, et al.
Publicado: (2021)

PS163. Serotonin Transporter Polymorphism in Severe Major Depressive Disorder in Indonesia
por: Arlisa, Wulandari, et al.
Publicado: (2016)

163. Infective Endocarditis in Qatar: Risk Factors, Clinical Characteristics, Microbiology, and Outcomes
por: Zaqout, Ahmed, et al.
Publicado: (2019)

P163: Patients for patient safety: translating anecdote to evidence base
por: Murphy, M
Publicado: (2013)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

163. Can Machine Learning Guide Antibiotic Initiation for Lower Respiratory Tract Infections?
por: Tang, Sarah, et al.
Publicado: (2023)

1238. The Novel Semisynthetic Saponin Adjuvant TQL1055 Enhances the Antibody Response to Pertussis Vaccine with an Improved Tolerability Profile over QS-21
por: Buzz, Chloe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iprbcmj06eaeed4s24647114us